Dragon Pain Numbing Roll-on

Lidocaine Hydrochloride


Genomma Lab Usa
Human Otc Drug
NDC 50066-411
Dragon Pain Numbing Roll-on also known as Lidocaine Hydrochloride is a human otc drug labeled by 'Genomma Lab Usa'. National Drug Code (NDC) number for Dragon Pain Numbing Roll-on is 50066-411. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Dragon Pain Numbing Roll-on drug includes Lidocaine Hydrochloride - 40 mg/g . The currest status of Dragon Pain Numbing Roll-on drug is Active.

Drug Information:

Drug NDC: 50066-411
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Dragon Pain Numbing Roll-on
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Lidocaine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Genomma Lab Usa
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:LIDOCAINE HYDROCHLORIDE - 40 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 24 Jul, 2021
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 09 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Genomma Lab USA
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1987647
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0650240060434
UPC stands for Universal Product Code.
UNII:V13007Z41A
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Amide Local Anesthetic [EPC]
Amides [CS]
Antiarrhythmic [EPC]
Local Anesthesia [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
50066-411-021 CONTAINER in 1 CARTON (50066-411-02) / 71 g in 1 CONTAINER24 Jul, 2021N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose topical analgesic

Product Elements:

Dragon pain numbing roll-on lidocaine hydrochloride lidocaine hydrochloride lidocaine lidocaine hydrochloride anhydrous alcohol water aminomethylpropanol caprylyl trisiloxane ceteth-20 phosphate steareth-21

Indications and Usage:

Use for the temporary relief of pain

Warnings:

Warnings for external use only do not use on large areas of the body, particularly over raw surfaces or blistered areas on wounds or damaged skin when using this product use only as directed avoid contact with eyes do not apply tight bandages do not apply a heating pad to treated skin do not use in large quantities stop use and ask a doctor if condition worsens or symptoms persist for more than 7 days symptoms clear up and occur again within a few days if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children to avoid accidental ingestion. if swallowed, get medical help or contact a poison control center immediately.

Do Not Use:

Warnings for external use only do not use on large areas of the body, particularly over raw surfaces or blistered areas on wounds or damaged skin when using this product use only as directed avoid contact with eyes do not apply tight bandages do not apply a heating pad to treated skin do not use in large quantities stop use and ask a doctor if condition worsens or symptoms persist for more than 7 days symptoms clear up and occur again within a few days if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children to avoid accidental ingestion. if swallowed, get medical help or contact a poison control center immediately.

When Using:

When using this product use only as directed avoid contact with eyes do not apply tight bandages do not apply a heating pad to treated skin do not use in large quantities

Dosage and Administration:

Directions use only as directed adults and children 12 years of age and older: apply to affected area not more than 3 to 4 times daily children under 12 years of age: ask a doctor

Stop Use:

Stop use and ask a doctor if condition worsens or symptoms persist for more than 7 days symptoms clear up and occur again within a few days

Package Label Principal Display Panel:

Principal display panel - 71 g container carton pomada dragon ® lidocaine hcl 4% pain numbing roll on max strength numbs pain fast hours of relief odor free keeps hands clean! blocks pain receptors no mess applicator! net wt 2.5 oz (71 g) principal display panel - 71 g container carton

Further Questions:

Questions or comments? call toll free 1-877-994-3666


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.